ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has 1 Year Target Estimate of $21


ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has a 1 Year Target Estimate of $21. The stock traded with the volume of 3.04 Million in the last trading session. ZIOPHARM Oncology Inc opened at $6.85 and closed by showing a decrease of -0.73%. The Bid price in the last session was $6.51 x 1000 and the Ask price was $7.22 x 2000. (The ask price is what sellers are willing to take for it. If you are selling a stock, you are going to get the bid price, if you are buying a stock you are going to get the ask price. The difference (or spread) goes to the broker/specialist that handles the transaction).

ZIOPHARM Oncology Inc has the Market Capitalization of 881.94 Million. The Stock has its 52-week High of $13.08 and 52-Week Low of $4.45 and it touched its 52-week high on Dec 2, 2015 and 52-Week Low on Jul 25, 2016.

ZIOPHARM Oncology Inc reported its last Earnings on Nov 03 AMC where the company reported Actual EPS of $-0.11/Share whereas, the Analyst Estimated EPS was $-0.11/share. The difference between Actual EPS and Estimated EPS was $0/share. This represented an Earnings Surprise of 0%. The company will report its next earnings on Feb 22 – Feb 27 (Est.).

1 number of analysts also provided their insight on ZIOPHARM Oncology Inc, where the Average Price Target for the stock is $21. They also projected Low Price Target as $21 while High Price Target is set at $21.

A number of analysts rated the stock as well: 1 analysts believe that the stock is a STRONG BUY while 0 reported it as Buy.4 analysts assigned a HOLD rating, 0 said it’s UNDERPERFORM and 0 say that this stock is a SELL.

ZIOPHARM Oncology Inc annual Divided is 0 while it’s Dividend Yield is 0%. The stock has its Price to Earnings (P/E) ratio of 0 and Forward Price to Earnings ratio of 0. The company has its Price to Sales (P/S) ratio of 123.69 where Price to Book (P/B) ratio of 0, Price to Cash Per share (P/C) of 9.4 and Price to Free Cash Flow (P/FCF) has a value of 0.

The company has its Return on Assets (ROA) of -123.7 Percent. Return on Equity (ROE) stands at 0% and Return on Investment (ROI) displays a value of -137.4%.

The stock is currently trading at Distance from 20-Day simple moving Average of 6.33% whereas, Distance from 50-Day Simple moving average is 15.43 Percent and Distance from 200-Day Simple Moving Average of 4.75 percent.

A look at performance overview of ZIOPHARM Oncology Inc depicts that Performance (Week) is 5.46 percent while Performance Month is 24.72%. Quarterly performance shows a value of 30.5% and Half Year Performance value stands at -12.66%. Yearly performance of the stock has the value of -48.32 percent. ZIOPHARM Oncology Inc has its YTD performance of -18.65 Percent. (YTD performance is the most important factor to consider; if YTD is negative, the stock is declining; if the YTD Performance value is Positive the stock is surging).

Insider Trades:

Many Insiders have done trades inside the company. The latest trade was made on 31 May 2016 where Chief Operating Officer Belbel (Caesar J) did a transaction type “Sell” in which 6667 shares were traded at a price of $7.74. Another insider trade includes Chief Executive Officer Cooper (Laurence James Neil) who also initiated a transaction in which 116667 shares were traded on 4 May 2016 as “Sell”. On 20 Apr 2016 Director Cannon (James Anthony) traded 15000 shares as “Buy” at $5.01. Director Weiser (Michael) Buy 15000 shares on 18 Apr 2016 at the price of $5.01.

Upgrades/Downgrades Report:

The latest Upgrades/Downgrades was done by Research firm Wells Fargo on 10-Aug-16 who Upgrade the stock from Underperform to Market Perform. Other firms have also Upgraded/Downgraded the stock. On 2-Jun-16, Raymond James took an action “Initiated”  to Mkt Perform. On 10-Mar-15, the stock was Downgrade to Neutral by Mizuho.